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Research
In industrialized societies, pulse pressure
(systolic minus diastolic blood pressure)
increases with age, a trend that accelerates in
the sixth decade when the diastolic blood pres-
sure begins to decrease (Franklin et al. 1997).
The increase in pulse pressure reﬂects arterial
aging and progressive vascular stiffening
(Lakatta and Levy 2003), with the predomi-
nant contribution from increased aortic stiff-
ness (Mitchell et al. 2004). Vascular oxidative
stress contributes to arterial aging (Lakatta
2003). Accordingly, known contributors to
vascular oxidative stress including obesity
(Kwagyan et al. 2005), smoking (Mahmud and
Feely 2003), hyperglycemia (van Dijk et al.
2002), and dyslipidemia (Miyagi et al. 2002)
are associated with increased pulse pressure.
Lead exposure is also associated with vascu-
lar oxidative stress (Vaziri 2002). In vivo
(Vaziri et al. 1999) and in vitro (Vaziri and
Ding 2001) studies of lead demonstrate
increased vascular reactive oxygen species gen-
eration. Lead accumulates in the vasculature of
the lead-exposed rat and remains after the
exposure has ended (Malvezzi et al. 2001). The
lead-exposed rat develops hypertension ame-
liorable by antioxidant therapy (Vaziri et al.
1997). These ﬁndings suggest that accumula-
tion of lead in the arterial tree may contribute
to arterial stiffness by inducing oxidative stress.
In industrialized societies, accumulation of
bone lead is many times greater than that
observed in cultures that do not use lead
(Drasch 1982). Therefore, bone lead may serve
as a proxy marker of lead accumulated in the
arterial tree. In fact, human autopsy studies
demonstrate age- and dose-dependent aortic
lead deposition and suggest that the aorta is
the next most lead-avid tissue after bone (Barry
and Mossman 1970; Schroeder and Tipton
1968). Although public health initiatives have
been successful at lessening environmental lead
exposures in the United States (Muntner et al.
2005), low-level lead exposure remains an
important contributor to all-cause and cardio-
vascular mortality (Menke et al. 2006).
The effect of low-level environmental
exposure to lead on blood pressure is an area
of ongoing scientiﬁc debate. Some investiga-
tors have found the relationship between low-
level lead exposure and blood pressure to be
inconsistent and weak (Nawrot et al. 2002;
Staessen et al. 1994), but several toxicologic
studies by have found that lead elevates blood
pressure (Khalil-Manesh et al. 1993; Vaziri
et al. 1997; Victery et al. 1982). Other inves-
tigators have noted the consistency of the
effect size of the blood lead–blood pressure
association, and its significance in meta-
analyses (Navas-Acien et al. 2007; Schwartz
1991, 1995). A limitation of this body of
work is the use of lead in blood as a metric of
exposure, where the median residence time of
lead is measured in days. Yet autopsy studies
indicate that around 95% of lead in the adult
human body is deposited in the skeleton, and
to the extent that the lead’s effect on blood
pressure can be attributed to chronic expo-
sures, a longer averaging time for exposure
would be more relevant for evaluating these
effects. For example, using K-X-ray fluores-
cence (KXRF) to directly measure levels of
lead retained in bone, we have found that
bone lead, compared with blood lead, more
accurately reflects cumulative lead exposure
(Hu et al. 1996b). We have also found bone
lead level to be more strongly associated than
blood lead level with blood pressure and
hypertension in adult men (Cheng et al.
2001; Hu et al. 1996a).
We examined the cross-sectional associa-
tion of community-level lead exposure with
pulse pressure in the Normative Aging Study,
a longitudinal cohort of men. We analyzed
this association using both bone and blood
lead levels, anticipating that the former, a
more accurate indicator of cumulative lead
exposure, would be more strongly associated
with pulse pressure.
Methods
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BACKGROUND: Pulse pressure increases with age in industrialized societies as a manifestation of
arterial stiffening. Lead accumulates in the vasculature and is associated with vascular oxidative
stress, which can promote functional and structural vascular disease.
OBJECTIVES: We tested the hypothesis that cumulative community-level lead exposure, measured
with K-X-ray ﬂuorescence, is associated with pulse pressure in a cohort of adult men.
METHODS AND RESULTS: In a cross-sectional analysis of 593 men not treated with antihypertensive
medication, tibia lead was positively associated with pulse pressure (p < 0.001). Adjusting for age,
race, diabetes, family history of hypertension, education, waist circumference, alcohol intake, smok-
ing history, height, heart rate, fasting glucose, and total cholesterol-to-HDL ratio, increasing quin-
tiles of tibia lead remained associated with increased pulse pressure (ptrend = 0.02). Men with tibia
lead above the median (19.0 µg/g) had, on average, a 4.2-mmHg (95% confidence interval,
1.9–6.5) higher pulse pressure than men with tibia lead level below the median. In contrast, blood
lead level was not associated with pulse pressure.
CONCLUSIONS: These data indicate that lead exposure may contribute to the observed increase in
pulse pressure that occurs with aging in industrialized societies. Lead accumulation may contribute
to arterial aging, perhaps providing mechanistic insight into the observed association of low-level
lead exposure with cardiovascular mortality.
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6 September 2007]Study population. Participants were from
the Normative Aging Study (NAS), a longitu-
dinalstudy of aging established by the Veterans
Administration in 1961. Male volunteers from
the Greater Boston, Massachusetts, area were
screened at entry and enrolled in the study if
they had no history of heart disease, hyperten-
sion, diabetes, cancer, peptic ulcer, gout, recur-
rent asthma, bronchitis, or sinusitis. Those with
either a systolic blood pressure > 140 mmHg or
a diastolicblood pressure > 90 mmHg were dis-
qualiﬁed. Between 1963 and 1968, 2,280 men
were enrolled; their ages at entry ranged from
21 to 80 years. Participants were asked toreturn
for follow-up examinations every 3–5 years,
and the attrition rate was roughly 1% per year
over the life of the study. Beginning in 1991,
we invited the men still being monitored by
the NAS to take part in a study of lead expo-
sure, as assessed by KXRF measurements. The
study was approved by the human subjects
committees of both the Boston Veterans
Administration Medical Center and the
Brigham and Women’s Hospital.
Bone and blood lead measurements. NAS
participants who gave their informed consent
reported to the outpatient General Clinical
Research Center of the Brigham and Women’s
Hospital in Boston, where we measured their
bone lead levels at two sites (the midtibial shaft
and the patella) with a KXRF instrument
(ABIOMED, Inc., Danvers, MA). The physi-
cal principles, technical speciﬁcations, and vali-
dation of this instrument have been described
in detail elsewhere (Burger et al. 1990; Hu
et al. 1990a, 1990b). Because the instrument
provides a continuous unbiased point estimate
(micrograms of lead per gram of bone mineral)
that oscillates around the true bone lead value,
it sometimes produces negative point estimates
when the true bone lead value is close to zero.
The instrument also provides an estimate of
the uncertainty associated with each measure-
ment that is derived from a goodness-of-fit
calculation of the spectrum curves and is equiv-
alent to a standard deviation (SD) if multiple
measurements were taken. Although a mini-
mally detectable limit calculation of twice this
SDhas been proposed for interpreting an indi-
vidual’s bone lead estimate (Gordon et al.
1993), retention of all point estimates has been
shown to make better use of the data in epi-
demiologic studies (Kim et al. 1995).The tech-
nicians measuring bone lead were blinded to
the participants’ health status. Thirty-minute
measurements were taken at the midshaft of
the left tibia and at the left patella. A priori we
chose to examine tibia lead as a marker of
cumulative lead exposure because tibia bone is
mostly cortical bone, whereas the patella is
mostly trabecular bone and has a greater
turnover rate (Hu et al. 1996b).
Blood samples were obtained and ana-
lyzed by graphite furnace atomic absorption
spectroscopy (GF-AAS; ESA Laboratories,
Chelmsford, MA); this instrument was cali-
brated after every 21 samples with National
Bureau of Standards’ blood lead standards
materials (Gaithersburg, MD). The limit
of detection for the GF-AAS method is
< 1 µg/dL; thus, values are expressed as integers
going down to 0 µg/dL. Ten percent of the
samples were run in duplicate; at least 10% of
the analyses were controls, and 10% were
blanks. In tests on reference samples from the
Centers for Disease Control and Prevention
(Atlanta, GA), the precision (the coefﬁcient of
variation) ranged from 8% for concentrations
between 10 and 30 µg/dL to 1% for higher
concentrations. In comparison with a National
Bureau of Standards’ target of 5.7 µg/dL,
24 measurements by this method gave a mean
of 5.3 µg/dL with an SD of 1.23 µg/dL.
Blood pressure measurements. During
each clinical visit, a physician using a standard
mercury sphygmomanometer with a 14-cm
cuff measured the participant’s blood pres-
sure. With the participant seated, the systolic
blood pressure and ﬁfth-phase diastolic blood
pressure were measured once in each arm to
the nearest 2 mmHg. For this study, the
mean of the right and left arm measurements
was used as each participant’s systolic and
diastolic blood pressures. Pulse pressure was
calculated as the mean systolic minus the
mean diastolic blood pressure. Heart rate was
recorded as beats per minute.
Physical parameters and medical history.
For each clinical visit, the NAS participant
reported to the study center in the morning
after an overnight fast and abstinence from
smoking. At the start of the visit, height and
weight were measured. Thereafter, a physician
took a complete medical history and conﬁrmed
the identity and purpose of medications taken
daily. Medications were considered anti-
hypertensive if they included a beta-blocker,
calcium channel blocker,diuretic, or other vas-
cular agent prescribed by the participant’s
physician. The participant also indicated
whether his mother or father had hypertension
that was diagnosed by a physician.Alcohol and
dietary intake were assessed with a standardized
semiquantitative food frequency questionnaire
(Willett et al. 1988), in which participants
reported the average frequency of each listed
food item consumed in the previous year. In
the present study, we examined sodium and
calcium intakes, which we calculated by multi-
plying the frequency of intake by the nutrient
content of the food items. We solicited infor-
mation on current and past history of smoking
using questions developed for the American
Thoracic Society (Ferris 1978).
Statistical analysis. The present analysis is
a cross-sectional examination of the associa-
tion of blood and bone lead levels with pulse
pressure in subjects with these measurement
made in the years 1991–1997. The partici-
pants for the present study were a subgroup
of the NAS cohort who underwent at least
one KXRF bone lead measurement and were
not on antihypertensive therapy at the time of
this measurement. Of the 1,262 men who
were seen for their regularly scheduled visits
between August 1991 and December 1997,
840 (66.6%) underwent KXRF measure-
ment. The most common reason given for
not having a measurement was the inconve-
nience involved in making anothervisit to the
bone lead laboratory on a separate day. As a
standard quality-control procedure, we
excluded seven men who had high uncer-
tainty estimates (> 10 µg/g) for bone lead
measurement (Hu et al. 1996b). A compari-
son of the group of men who had KXRF
examinations with the group of men who
either did not have KXRF examinations or
whose bone lead measurements had a high
degree of uncertainty revealed no significant
differences with respect to age, race, body
mass index (BMI), smoking, alcohol con-
sumption, systolic or diastolic blood pressure,
family history of hypertension,dietary sodium
or calcium intake, and blood lead level
(Cheng et al. 2001; Hu et al. 1996a). Among
the 833 participants in the bone lead study,
233 were on antihypertensive therapy at the
time of their study visit, and seven men did
not have blood pressure data to calculate
pulse pressure. We therefore included
593 men in this analysis. The blood pressure
measurement typically preceded the lead
determinations, and the median (interquartile
range) number of days between these meas-
urements was 18 (8–39).
For each of the two lead biomarkers (blood
lead and tibia lead), we used multiple linear
regression to compare the mean pulse pressure
across quintiles of the lead biomarker. We used
quintiles of lead level to limit the inﬂuence of
outliers and to not assume a linear relationship
between lead level and pulse pressure. We
determined covariates for our core models
based on known determinants of bone and
blood lead level, blood pressure, risk factors for
arterial aging, and physiologic determinants of
pulse pressure. Our regression analyses were all
adjusted for the following variables, all of
which were assessed at the time of bone lead
measurement: age (years), age squared, height
(meters), race (white vs. nonwhite), heart rate
(beats/minute), waist circumference (centime-
ters), diabetes, family history of hypertension
(yes/no), education level achieved, smoking
(pack-years), alcohol intake (grams per day),
fasting plasma glucose (mmol), and ratio of
total cholesterol to HDL (high-density
lipoprotein) cholesterol (Hu et al. 1996a,
1996b; Kwagyan et al. 2005; Mahmud and
Feely 2003; Miyagi et al. 2002; van Dijk et al.
2002). We did not adjust our analyses for
Lead exposure and pulse pressure
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which the pulse pressure is mathematically
derived. We used an F-test (with p = Pr[F5-
1,593-5 > F]) to evaluate the overall association
between level of lead biomarker and pulse pres-
sure, and we computed tests of linear trend by
fitting models with an ordinal term, which
took on the values of each biomarker quintile
(i.e., 1, 2, 3, 4, 5). We ﬁt additional models
that further adjusted for dietary sodium and
calcium as well as total caloric intake.
All analyses were conducted with the SAS
software program (version 8.2; SAS Institute
Inc., Cary, NC) with p < 0.05 as the level of
statistical significance. All authors had full
access to the data and take responsibility for
its integrity. All authors have read and agree
to the manuscript as written.
Results
The blood lead levels of the study population
ranged from < 1 to 35 µg/dL, with a mean
(± SD) of 6.12 ± 4.03 µg/dL. These values are
representative of community-level (i.e.,
nonoccupational) exposure in the U.S. gen-
eral population in this age range (Pirkle et al.
1994). The mean levels (± SD) of blood lead
among the first through fifth quintiles were
2.3 ± 0.8, 3.9 ± 0.3, 5.4 ± 0.5, 7.4 ± 0.6, and
12.4 ± 4.4 µg/dL, respectively. The mean lev-
els of tibia lead among the first through the
ﬁfth quintiles were 7.4 ± 3.2, 14.1 ± 1.4, 18.9
± 1.4, 24.9 ± 2.2, and 40.9 ± 14.0 µg/g bone,
respectively.
We examined participants’ characteristics
in relation to quintile of tibia lead level to
provide insight into potential confounders of
the association between lead and pulse pres-
sure (Table 1). Of particular note, higher tibia
lead level was associated with age, smoking,
lower education level, and shorter height.
None of these characteristics varied across
quintile of blood lead level (data not shown)
[see Hu et al. (1996b) for more details on
determinants of bone and blood lead levels].
We examined the progression of systolic
and diastolic blood pressure and pulse pres-
sure with age, categorized in 5-year incre-
ments (Figure 1). As demonstrated in other
industrialized populations, the systolic blood
pressure and pulse pressure increased with
age, whereas the diastolic blood pressure
decreased after the sixth decade (Franklin
et al. 1997; Lakatta and Levy 2003).
We evaluated unadjusted, age-adjusted,
and multivariable-adjusted correlations of
blood and bone lead levels with systolic and
diastolic blood pressure (Table 2). Blood lead
level tended to be directly associated with sys-
tolic and diastolic blood pressure. Tibia lead
level tended to be directly associated with sys-
tolic blood pressure and tended to be
inversely associated diastolic blood pressure.
After multivariable adjustment, the direct
association of blood lead with diastolic blood
pressure remained signiﬁcant.
We observed significant differences in
pulse pressure across quintiles of bone lead
but not blood lead after multivariable adjust-
ment. Tibia lead–level quintile was signifi-
cantly associated with pulse pressure (overall
F-test, p < 0.01), with pulse pressure increas-
ing with tibia lead–level quintile (ptrend =
0.02; Table 3). Men with tibia lead level
above the median (19.0 µg/gm) had, on aver-
age, a mean pulse pressure that was 4.2
mmHg greater [95% confidence interval
(CI), 1.9–6.5] than men with tibia lead levels
below the median. Blood lead was not associ-
ated with pulse pressure (overall F-test, p =
0.20). Dietary intake of sodium, dietary
intake of calcium, and hematocrit were all
added individually to our models but did not
substantially change these results. In addition,
we did not find a significant interaction
between dietary calcium intake and tibia lead
quintile in determining the pulse pressure.
The association of patella lead with pulse
pressure was of borderline statistical signifi-
cance (data not shown).
Analyses were repeated excluding the 14
nonwhite participants; the association of tibia
lead with pulse pressure was not changed. We
performed additional analysis including men
treated with antihypertensive therapy (total
n = 826), and adjusting for antihypertensive
therapy (using vs. not using). In this analysis,
tibia lead level remained associated with pulse
pressure (Overall F-test p = 0.02, ptrend =
0.04), though the effect of tibia lead quintile
on pulse pressure was somewhat attenuated
[highest vs. lowest quintile, difference in pulse
pressure = 1.9 mmHg (95% CI, 1.4–5.1)].
Discussion
In this study of 593 older men, cumulative
community-level lead exposure was indepen-
dently associated with increased pulse pres-
sure. Speciﬁcally, we observed this association
with respect to bone lead level, but not blood
lead level. These results are consistent with the
concept that bone lead level is a better indica-
tor of cumulative lead exposure. These data
may provide some mechanistic insight into the
association of low-level lead exposure with car-
diovascular mortality (Menke et al. 2006).
The pulse pressure—the difference
between the systolic and the diastolic blood
pressures—is receiving increasing attention as
both an indicator of and a risk factor for car-
diovascular disease (Safar et al. 2003). Our
data support the well-described progression of
pulse pressure with age, with progressively
Perlstein et al.
1698 VOLUME 115 | NUMBER 12 | December 2007 • Environmental Health Perspectives
Table 1. Characteristics of men by quintile of tibia lead (µg/g). 
Quintile tibia lead level [mean (range)]
Lowest (n = 111) 2 (n = 119) 3 (n = 122) 4 (n = 119) Highest (n = 122)
Characteristic 7.4 (–3 to 11) 14.1 (12 to 16) 18.9 (17 to 21) 24.9 (22 to 29) 40.9 (30 to 126) p-Value
Age (years) 63.0 ± 7.0 64.4 ± 6.9 66.8 ± 7.4 68 ± 7.3 70.5 ± 6.7 < 0.001
Race (nonwhite)  2 (1.8) 2 (1.7) 2 (1.6) 3 (2.5) 5 (4.1) 0.21
Diabetes mellitus diagnosis 4 (3.6) 4 (3.4) 7 (5.7) 6 (5.0) 13 (11) 0.02
Smoking history (pack-years) 13 ± 14 14 ± 15 18 ± 17 20 ± 16 19 ± 17 0.002
Alcohol history (g/day) 12 ± 15 12 ± 16 15 ± 21 16 ± 19 11 ± 15 0.22
Dietary sodium intake (mg/day) 3,559 ± 1,562 3,930 ± 1,916 3,925 ± 1,736 3,850 ± 1,723 4,141 ± 2,055 0.21
Dietary calcium intake (mg/day) 819 ± 393 897 ± 492 856 ± 453 847 ± 524 833 ± 444 0.77
Family history of hypertension 17 (18) 37 (34) 30 (27) 24 (22) 16 (14) 0.11
Education level (graduated high school) 71 (64) 71 (60) 59 (48) 58 (49) 42 (34) < 0.001
Systolic blood pressure (mmHg) 133 ± 16 129 ± 14 133 ± 15 137 ± 19 137 ± 17 0.001
Diastolic blood pressure (mmHg) 83 ± 9.0 81 ± 7.9 80 ± 9.7 80 ± 10 80 ± 9.3 0.008
Pulse pressure (mmHg) 50 ± 14 49 ± 12 53 ± 14 57 ± 15 58 ± 14 < 0.001
Heart rate (beats/min) 75 ± 10 72 ± 10.3 72 ± 9.6 73 ± 11 74 ± 12 0.09
BMI (kg/m2) 28 ± 3.6 27 ± 3.5 28 ± 3.9 28 ± 3.6 28 ± 3.4 0.92
Waist circumference (cm) 98 ± 10 97 ± 9.9 98 ± 9.8 98 ± 9.7 98 ± 8.9 0.85
Height (m) 1.75 ± 0.07 1.74 ± 0.06 1.74 ± 0.06 1.72 ± 0.06 1.71 ± 0.06 < 0.001
Fasting plasma glucose (mmol) 5.83 ± 1.1 5.78 ± 1.3 6.00 ± 2.2 6.05 ± 1.4 6.11 ± 1.6 0.41
Hematocrit (%) 44 ± 2.8 44 ± 2.9 44 ± 2.7 44 ± 3.0 44 ± 3.5 0.40
Total cholesterol to HDL ratio 5.1 ± 1.5 5.0 ± 1.4 4.9 ± 1.4 4.8 ± 1.2 5.1 ± 1.5 0.54
Blood lead level (µg/dL) 4.9 ± 2.9 5.3 ± 3.6 5.6 ± 3.5 6.7 ± 3.8 8.1 ± 5.2 < 0.001
Comparisons are by overall F-test for continuous variables and by chi-square test for categorical variables. Values are mean ± SD or no. (%). higher systolic pressures throughout adult-
hood, and the diastolic pressure leveling off
among men in the sixth decade and declining
in older men (Franklin et al. 1997).
The progression of pulse pressure with age
is largely attributed to progressive aortic stiffen-
ing (Mitchell et al. 2004). Age-related arterial
stiffening is attributable to structural and func-
tional changes in the vasculature (Lakatta and
Levy 2003). Structurally, vascular aging is asso-
ciated with increased collagen content,
increased elastin fractures, increased calciﬁca-
tion, and reduced elastin content. Functionally,
vascular aging is associated with impaired
endothelial function and endothelium-
dependent vasodilation (Gerhard et al. 1996).
A fundamental and shared mechanism for
vascular structural and functional changes is
vascular oxidative stress (Lakatta 2003; Touyz
2004). Observations in lead-exposed animals
strongly suggest that vascular oxidative stress
plays a key role in the pathophysiology of lead-
induced hypertension and vascular disease
(Farmand et al. 2005; Malvezzi et al. 2001; Ni
et al. 2004; Vaziri 2002; Vaziri and Ding
2001; Vaziri and Sica 2004; Vaziri et al. 1997,
1999a, 1999b, 2001, 2003). Human studies
indicate that lead accumulates in the aorta
(Barry and Mossman 1970; Schroeder and
Tipton 1968) and that lead exposure is associ-
ated with oxidative stress in humans (Gurer-
Orhan et al. 2004; Ye et al. 1999), although to
our knowledge the association of lead exposure
with vascular oxidative stress in humans has
not been speciﬁcally examined.
In this study, tibia bone lead was more
strongly associated with pulse pressure than
was patella bone lead (data not shown). The
tibia bone is mostly cortical bone, whereas the
patella is mostly trabecular bone and has a
greater turnover rate (Hu et al. 1996b). Tibia
lead has a longer half-life and is considered a
better marker of cumulative lead exposure
than patella lead. The stronger association of
tibia lead with pulse pressure is consistent
with an effect of long-term lead exposure on
vascular structure and function. Interestingly,
blood lead level was positively associated with
diastolic blood pressure, causing us to specu-
late that circulating lead may have more of an
inﬂuence on vascular tone than vascular struc-
ture, though this requires further exploration.
We found that men with bone lead levels
above the median had pulse pressures that
were on average 4.2 mmHg higher compared
with men with lower bone lead levels. The
magnitude of this association is numerically
small but potentially clinically signiﬁcant. In
the Conduit Artery Function Evaluation
(CAFE) study of the Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT) compar-
ing amlodipine ± perindopril versus atenolol
± thiazide in the treatment of hypertension, a
3-mmHg decrement in central pulse pressure
conferred a cardiorenal advantage to the
amlodipine ± perindopril strategy (Williams
et al. 2006). Pulse pressure is an important
indicator of cardiovascular risk becasue pulse
pressure is associated with inflammation
(Abramson et al. 2002), coronary heart dis-
ease (Franklin et al. 1999), and cardiovascular
death (Domanski et al. 2001). The associa-
tion we have demonstrated between lead
exposure and pulse pressure may provide
mechanistic insight into the association of
lead exposure with cardiovascular death
(Menke et al. 2006).
Because this is a cross-sectional study, we
cannot explicitly examine the temporal associ-
ation between lead exposure and subsequent
pulse pressure or individual changes in pulse
pressure. Nonetheless, our bone lead meas-
ures, particularly tibia lead, do reflect expo-
sures that occurred over the past years to
decades, suggesting a temporal ordering of the
association that we observed between bone
lead and pulse pressure. Moreover, reverse
causation—the situation in which pulse
pressure affects lead exposure—is highly
unlikely. Blood pressure was measured once
in each arm; averaging these values increases
the precision of our measurement. It is possi-
ble, however, that differences in the blood
pressure between the arms due to subclavian
stenosis or other processes may introduce
error into our blood pressure determination
and limit the precision of our lead effect esti-
mates. Although our results were adjusted for
numerous important potential confounders,
we cannot rule out the possibility that the
association we found derives from confound-
ing by unmeasured factors or that categorical
tibia lead level may not entirely account for
the association of bone lead with aging. The
data suggest that there may be a threshold to
the effect of lead exposure on pulse pressure,
because only the top two quintiles of tibia
lead were associated with a mean pulse pres-
sure greater than that of the ﬁrst quintile. It is
possible that selective survival biased our ﬁnd-
ings in this older cohort of men, in that sur-
vival may be related to lower lead exposures
and lower pulse pressure; even so, such bias
would tend to make our results a conservative
estimate of the adverse association between
bone lead and pulse pressure.
Lead exposure and pulse pressure
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Table 3. Multivariable-adjusted group mean differ-
ences in pulse pressure by tibia lead and blood
lead level quintile. 
Adjusted mean
difference in
Quintile pulse pressure 95% CI Ptrend
Tibia lead 0.02
Highest 2.58 –1.15 to 6.33
Fourth 2.64 –0.93 to 6.21
Third –0.73 –4.27 to 2.82
Second –3.02 –6.48 to 0.44
Lowest 0.00 Referent
Blood lead 0.82
Highest –1.49 –4.93 to 1.94
Fourth –1.39 –4.94 to 2.15
Third –2.56 –5.78 to 0.67
Second –4.37 –7.88 to –0.86
Lowest 0.00 Referent
Analyses are adjusted for age (years), age squared, height
(m), race (white vs. nonwhite), heart rate (beats/min), edu-
cation level achieved, waist circumference (cm), diabetes,
family history of hypertension (yes/no), smoking (pack-
years), alcohol intake (g/day), fasting plasma glucose
(mmol/L), and ratio of total cholesterol to HDL cholesterol.  Figure 1. Arterial pressure parameters (mean ± SD) by age group. 
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Table 2. Spearman correlations between lead bio-
marker levels and blood pressure (BP) components.
Systolic BP Diastolic BP
rp -Value rp -Value
Tibia lead level (µg/g)
Unadjusted 0.13 < 0.01 –0.14 < 0.01
Age-adjusted 0.05 0.21 –0.06 0.14
Multivariable-adjusted 0.06 0.15 –0.02 0.63
Blood lead level (µg/dL)
Unadjusted 0.08 0.05 0.09 0.03
Age-adjusted 0.07 0.11 0.11 0.01
Multivariable-adjusted 0.05 0.28 0.12 0.01Perlstein et al.
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Although lead exposure has been associated
with elevated blood pressure in women (Nash
et al. 2003) and blacks (Vupputuri et al. 2003),
our ﬁndings are limited to Caucasian men. This
cohort of men had exposures to lead before
major public health reforms that removed lead
from paint and gasoline, and they may have
been further exposed in their military careers,
making their typical historical exposures higher
than current exposure levels. A sufficient
threshold of arterial aging needs to be achieved
before brachial pulse pressure begins to widen;
therefore, the association of lead and pulse
pressure may not be present in younger popu-
lations (O’Rourke and Hashimoto 2007).
Also, in older populations, the association of
lead exposure with pulse pressure may be
attenuated by selective survival, because both
lead exposure and pulse pressure are strong
predictors of mortality (Domanski et al. 2001;
Schober et al. 2006). Finally, studies directly
examining the association of lead exposure
with vascular function and pulse hemodynam-
ics are necessary to better deﬁne the relation-
ship between lead exposure and arterial aging.
In conclusion, we found that cumulative
lead exposure, as reﬂected by bone lead level,
was independently associated with increased
pulse pressure in a cohort of middle-aged and
older men with community-level lead expo-
sure. These ﬁndings implicate vascular accu-
mulation of lead in the pathogenesis of
vascular stiffening, a mechanism consistent
with the ﬁndings of aortic lead deposition in
humans and increased vascular oxidative stress
in the lead-exposed animal. Future work will
determine the effect of lead exposure on the
progression of pulse pressure with aging. We
suggest that further examinations of the asso-
ciation of lead exposure on arterial pressure
should use bone lead level as an indicator of
cumulative lead exposure.
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